| Host: |
Rabbit |
| Applications: |
WB/IF/ICC/IP/ELISA |
| Reactivity: |
Human/Mouse/Rat |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
PBS with 0.09% Sodium Azide, 50% Glycerol, pH 7.3. |
| Purification: |
Affinity purification |
| Concentration: |
Lot specific |
| Dilution Range: |
WB:1:500-1:2000IF/ICC:1:50-1:200IP:0.5 Mu g-4 Mu g antibody for 200 Mu g-400 Mu g extracts of whole cellsELISA:Recommended starting concentration is 1 Mu g/mL. Please optimize the concentration based on your specific assay requirements |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
POLR2A |
| Gene ID: |
5430 |
| Uniprot ID: |
RPB1_HUMAN |
| Immunogen Region: |
1-1970 |
| Specificity: |
Recombinant fusion protein containing a sequence corresponding to amino acids 1-260 of human POLR2A (NP_000928.1). |
| Immunogen Sequence: |
MHGGGPPSGDSACPLRTIKR VQFGVLSPDELKRMSVTEGG IKYPETTEGGRPKLGGLMDP RQGVIERTGRCQTCAGNMTE CPGHFGHIELAKPVFHVGFL VKTMKVLRCVCFFCSKLLVD SNNPKIKDILAKSKGQPKKR LTHVYDLCKGKNICEGGEEM DNKFGVEQPEGDEDLTKEKG HGGCGRYQPRIRRSGLELYA EWKHVNEDSQEKKILLSPER VHEIFKRISDEECFVLGME |
| Post Translational Modifications | The tandem heptapeptide repeats in the C-terminal domain (CTD) can be highly phosphorylated. The phosphorylation activates Pol II. Phosphorylation occurs mainly at residues 'Ser-2' and 'Ser-5' of the heptapeptide repeat and is mediated, at least, by CDK7 and CDK9. CDK7 phosphorylation of POLR2A associated with DNA promotes transcription initiation by triggering dissociation from DNA. Phosphorylation also takes place at 'Ser-7' of the heptapeptide repeat, which is required for efficient transcription of snRNA genes and processing of the transcripts. The phosphorylation state is believed to result from the balanced action of site-specific CTD kinases and phosphatases, and a 'CTD code' that specifies the position of Pol II within the transcription cycle has been proposed. Dephosphorylated by the protein phosphatase CTDSP1. Dephosphorylated at 'Ser-2' following UV irradiation. Among tandem heptapeptide repeats of the C-terminal domain (CTD) some do not match the Y-S-P-T-S-P-S consensus, the seventh serine residue 'Ser-7' being replaced by a lysine. 'Lys-7' in these non-consensus heptapeptide repeats can be alternatively acetylated, methylated and dimethylated. EP300 is one of the enzyme able to acetylate 'Lys-7'. Acetylation at 'Lys-7' of non-consensus heptapeptide repeats is associated with 'Ser-2' phosphorylation and active transcription. Regulates initiation or early elongation steps of transcription specially for inducible genes. Methylated at Arg-1810 prior to transcription initiation when the CTD is hypophosphorylated, phosphorylation at Ser-1805 and Ser-1808 preventing this methylation. Symmetrically or asymmetrically dimethylated at Arg-1810 by PRMT5 and CARM1 respectively. Symmetric or asymmetric dimethylation modulates interactions with CTD-binding proteins like SMN1/SMN2 and TDRD3. SMN1/SMN2 interacts preferentially with the symmetrically dimethylated form while TDRD3 interacts with the asymmetric form. Through the recruitment of SMN1/SMN2, symmetric dimethylation is required for resolving RNA-DNA hybrids created by RNA polymerase II, that form R-loop in transcription terminal regions, an important step in proper transcription termination. CTD dimethylation may also facilitate the expression of select RNAs. Among tandem heptapeptide repeats of the C-terminal domain (CTD) some do not match the Y-S-P-T-S-P-S consensus, the seventh serine residue 'Ser-7' being replaced by a lysine. 'Lys-7' in these non-consensus heptapeptide repeats can be alternatively acetylated, methylated, dimethylated and trimethylated. Methylation occurs in the earliest transcription stages and precedes or is concomitant to 'Ser-5' and 'Ser-7' phosphorylation. Dimethylation and trimehtylation at 'Lys-7' of non-consensus heptapeptide repeats are exclusively associated with phosphorylated CTD. Ubiquitinated by WWP2 leading to proteasomal degradation. Following transcription stress, the elongating form of RNA polymerase II (RNA pol IIo) is ubiquitinated by NEDD4 on Lys-1268 at DNA damage sites without leading to degradation: ubiquitination promotes RNA pol IIo backtracking to allow access by the transcription-coupled nucleotide excision repair (TC-NER) machinery. At stalled RNA pol II where TC-NER has failed, RBX1-mediated polybiquitination at Lys-1268 may lead to proteasome-mediated degradation in a UBAP2- and UBAP2L-dependent manner.presumably to halt global transcription and enable 'last resort' DNA repair pathways. |
| Function | Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates. Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol II pre-initiation complex (PIC) is recruited to DNA promoters, with focused-type promoters containing either the initiator (Inr) element, or the TATA-box found in cell-type specific genes and dispersed-type promoters that often contain hypomethylated CpG islands usually found in housekeeping genes. Once the polymerase has escaped from the promoter it enters the elongation phase during which RNA is actively polymerized, based on complementarity with the template DNA strand. Transcription termination involves the release of the RNA transcript and polymerase from the DNA. Forms Pol II active center together with the second largest subunit POLR2B/RPB2. Appends one nucleotide at a time to the 3' end of the nascent RNA, with POLR2A/RPB1 most likely contributing a Mg(2+)-coordinating DxDGD motif, and POLR2B/RPB2 participating in the coordination of a second Mg(2+) ion and providing lysine residues believed to facilitate Watson-Crick base pairing between the incoming nucleotide and template base. Typically, Mg(2+) ions direct a 5' nucleoside triphosphate to form a phosphodiester bond with the 3' hydroxyl of the preceding nucleotide of the nascent RNA, with the elimination of pyrophosphate. The reversible pyrophosphorolysis can occur at high pyrophosphate concentrations. Can proofread the nascent RNA transcript by means of a 3' -> 5' exonuclease activity. If a ribonucleotide is mis-incorporated, backtracks along the template DNA and cleaves the phosphodiester bond releasing the mis-incorporated 5'-ribonucleotide. Through its unique C-terminal domain (CTD, 52 heptapeptide tandem repeats) serves as a platform for assembly of factors that regulate transcription initiation, elongation and termination. CTD phosphorylation on Ser-5 mediates Pol II promoter escape, whereas phosphorylation on Ser-2 is required for Pol II pause release during transcription elongation and further pre-mRNA processing. Additionally, the regulation of gene expression levels depends on the balance between methylation and acetylation levels of the CTD-lysines. Initiation or early elongation steps of transcription of growth-factor-induced immediate early genes are regulated by the acetylation status of the CTD. Methylation and dimethylation have a repressive effect on target genes expression. Cooperates with mRNA splicing machinery in co-transcriptional 5'-end capping and co-transcriptional splicing of pre-mRNA. RNA-dependent RNA polymerase that catalyzes the extension of a non-coding RNA (ncRNA) at the 3'-end using the four ribonucleoside triphosphates as substrates. An internal ncRNA sequence near the 3'-end serves as a template in a single-round Pol II-mediated RNA polymerization reaction. May decrease the stability of ncRNAs that repress Pol II-mediated gene transcription. (Microbial infection) Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicase and transcriptase for the viral RNA circular genome. |
| Protein Name | Dna-Directed Rna Polymerase Ii Subunit Rpb1Rna Polymerase Ii Subunit B13'-5' ExoribonucleaseDna-Directed Rna Polymerase Ii Subunit ADna-Directed Rna Polymerase Iii Largest SubunitRna-Directed Rna Polymerase Ii Subunit Rpb1 |
| Database Links | Reactome: R-HSA-112382Reactome: R-HSA-113418Reactome: R-HSA-167152Reactome: R-HSA-167158Reactome: R-HSA-167160Reactome: R-HSA-167161Reactome: R-HSA-167162Reactome: R-HSA-167172Reactome: R-HSA-167200Reactome: R-HSA-167238Reactome: R-HSA-167242Reactome: R-HSA-167243Reactome: R-HSA-167246Reactome: R-HSA-167287Reactome: R-HSA-167290Reactome: R-HSA-168325Reactome: R-HSA-203927Reactome: R-HSA-5578749Reactome: R-HSA-5601884Reactome: R-HSA-5617472Reactome: R-HSA-674695Reactome: R-HSA-6781823Reactome: R-HSA-6781827Reactome: R-HSA-6782135Reactome: R-HSA-6782210Reactome: R-HSA-6796648Reactome: R-HSA-6803529Reactome: R-HSA-6807505Reactome: R-HSA-72086Reactome: R-HSA-72163Reactome: R-HSA-72165Reactome: R-HSA-72203Reactome: R-HSA-73776Reactome: R-HSA-73779Reactome: R-HSA-75953Reactome: R-HSA-75955Reactome: R-HSA-76042Reactome: R-HSA-77075Reactome: R-HSA-8851708Reactome: R-HSA-9018519Reactome: R-HSA-9670095 |
| Cellular Localisation | NucleusCytoplasmChromosomeHypophosphorylated Form Is Mainly Found In The CytoplasmWhile The Hyperphosphorylated And Active Form Is NuclearCo-Localizes With Kinase Srpk2 And Helicase Ddx23 At Chromatin Loci Where Unscheduled R-Loops Form |
| Alternative Antibody Names | Anti-Dna-Directed Rna Polymerase Ii Subunit Rpb1 antibodyAnti-Rna Polymerase Ii Subunit B1 antibodyAnti-3'-5' Exoribonuclease antibodyAnti-Dna-Directed Rna Polymerase Ii Subunit A antibodyAnti-Dna-Directed Rna Polymerase Iii Largest Subunit antibodyAnti-Rna-Directed Rna Polymerase Ii Subunit Rpb1 antibodyAnti-POLR2A antibodyAnti-POLR2 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
